FDA Labels Germ DNA Stabilizer Device as Class II
Published Date: 5/6/2026
Rule
Summary
The FDA is officially putting a special label (Class II) on devices that keep tiny germs’ DNA stable in medical samples. This change makes sure these devices are safe and work well, while also making it easier and faster for new, helpful devices to reach patients. The new rules started May 6, 2026, and could save time and money for companies making these devices.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Device Reclassified to Class II
The FDA officially classed devices that preserve and stabilize microbial nucleic acids as Class II (special controls) effective May 6, 2026; the classification was applicable on November 3, 2021. Because this was done through the De Novo process, this device type can serve as a predicate for future devices so other sponsors may use the less-burdensome 510(k) pathway instead of a De Novo request or premarket approval.
Easier Patient Access to Microbiome Tests
The FDA says this Class II classification will enhance patients' access to beneficial innovative devices by reducing regulatory burdens. That means patients may see new devices for stabilizing microbial nucleic acids reach clinical use more quickly after May 6, 2026.
510(k) Premarket Notification Requirement
Devices of this type are subject to premarket notification under section 510(k) of the FD&C Act unless and until FDA exempts them. Sponsors must therefore prepare and submit a 510(k) to market these Class II devices.
New Special Controls: Labeling and Studies
The rule sets special controls requiring specific labeling and validation studies: labels must list specimen types, device description, a warning that the device is not for detecting specific pathogens, and a warning to use only with legally marketed assays. Sponsors must also provide detailed design verification and validation documentation, including microorganism panels, extraction platforms, assay protocols, bioinformatic pipelines, and usability studies for collection when applicable.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-08750, Extension of Postponement of Effectiveness for Certain Provisions of Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)
The EPA is hitting the pause button again on some rules about a chemical called TCE, which is used in workplaces. This means certain limited uses of TCE won’t have to follow new restrictions just yet, while courts review the rules. If you work with TCE, this delay gives you more time before changes kick in, starting May 18, 2026.
Next: 2026-08812, Medical Devices; Immunology and Microbiology Devices; Classification of the Circulating Tumor Cell Enrichment Device
The FDA is officially classifying the circulating tumor cell enrichment device as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to innovative cancer-fighting tools faster and keeps the device safe and effective. The new rules take effect May 6, 2026, and could save time and money for makers and users of this device.